Alembic Pharmaceuticals Limited — PPTs, 04-08-2026: Investor Presentation

Alembic Pharma reported a strong Q1 FY27, with revenue up 26% year-over-year to INR 2,150 Cr and reported profit after tax climbing 12% YoY to INR 173 Cr. EBITDA before R&D also rose 23% YoY to INR 523 Cr, showcasing a robust 24% margin.

Growth was broad-based: US Formulation revenue soared 49% YoY to INR 778 Cr, boosted by key product launches. India Branded Business grew 7% to INR 642 Cr, maintaining its 21st market rank. Ex-US Formulation increased 17% to INR 383 Cr, while the API segment jumped 33% to INR 346 Cr, supported by a strong order book.

The company launched 7 products in the US during the quarter, with plans for 15+ more launches this fiscal year. Strategic focus includes expanding the US branded business and advancing the R&D pipeline, particularly in peptide development. Alembic is also committed to sustainability, targeting Net Zero by 2050 and water neutrality by 2027.